❌

Reading view

Liquid biopsy- A pivotal test to help navigate clinical decisions at a precision center in India!

J Liq Biopsy. 2025 Aug 9;9:100323. doi: 10.1016/j.jlb.2025.100323. eCollection 2025 Sep.

ABSTRACT

Liquid biopsy, specifically circulating tumor DNA (ctDNA) analysis, has emerged as a transformative tool in precision oncology, providing real-time, minimally invasive characterizations of the tumor and tumor dynamics. While tissue biopsy is a critical tool for baseline diagnosis of malignancy, it is often limited by sampling constraints and an inability to capture tumor heterogeneity. In this study, we explored the clinical utility of serial ctDNA testing in guiding therapeutic decisions across a cohort of 30 patients with diverse solid tumors. Our real-world analysis demonstrates that ctDNA profiling meaningfully influenced treatment escalation, de-escalation, disease monitoring, and early relapse prediction. Cases where ctDNA positivity indicated minimal residual disease prompted timely escalation of therapy, while ctDNA clearance allowed safe treatment de-intensification, minimizing toxicity without compromising outcomes. Longitudinal ctDNA monitoring provided a dynamic, non-invasive method for assessing treatment response and detecting recurrence months before radiological progression. Our study highlights the potential of integrating liquid biopsy into routine clinical practice to enable dynamic treatment monitoring, early detection of therapeutic resistance, and more informed, personalized decision-making across various cancer types.

PMID:40919127 | PMC:PMC12409318 | DOI:10.1016/j.jlb.2025.100323

  •  

The WHO global landscape of cancer clinical trials

Nature Medicine, Published online: 09 September 2025; doi:10.1038/s41591-025-03926-x

This Review of the WHO’s International Clinical Trials Registry Platform presents a snapshot of the global cancer trial landscape and provides critical empirical evidence to inform policy, practice and investment.
  •  

STAT+: FDA greenlights trial of gene-edited pig kidneys as treatment for end-stage kidney disease

DOVER, N.H. — Not long after he woke from surgery in June, Bill Stewart made a  pact with his newest organ. He wasn’t sure how long the thing would last. The doctors had been up-front from the get-go: It could be three months or six, one year or four. Still, the uncertainty hit him as he started getting back preliminary lab results, which were okay but left room for improvement. “My pig kidney and I had a little conversation while I was laying there. I just basically said, ‘I’m going to do everything I can to make sure that you stay healthy, and I appreciate you doing everything you can to keep me upright and breathing,” Stewart said.

It’s been almost three months, and Stewart is home, back to work, and has even been able to go e-biking on a lakeside trail with his wife, blessedly untethered to the grueling schedules of dialysis for the first time in years, all thanks to a gene-edited Yucatan miniature pig named Lavender. 

Stewart is the most recent recipient of a pig kidney — but chances are, he won’t hold that distinction for long. On Monday, eGenesis, a Cambridge-based biotechnology company, announced that it had been cleared by the Food and Drug Administration to begin a trial of kidneys from donor pigs that have been CRISPR’d to make their organs more human-friendly. Now, Massachusetts researchers will be performing more surgeries like Stewart’s to see whether these animal parts could serve as a lifeline for people with end-stage renal disease.

Continue to STAT+ to read the full story…

© Cheryl Senter for STAT

  •  

Clinical applications of cell-free DNA-based liquid biopsy analysis

Transl Oncol. 2025 Nov;61:102519. doi: 10.1016/j.tranon.2025.102519. Epub 2025 Sep 6.

ABSTRACT

Liquid biopsies, particularly those involving circulating tumor DNA (ctDNA) from patient blood, have emerged as crucial and minimally invasive adjuncts to standard tissue-based testing. ctDNA testing enables the identification of actionable mutations for targeted therapy and can be routinely used when tissue samples are unavailable for genotyping. Compared to tissue-based testing, ctDNA testing has the advantages of capturing spatial or temporal genomic heterogeneity and facilitating repeated assessments. The utility of liquid biopsies extends to multiple clinical applications, including cancer diagnosis, treatment monitoring, and minimal residual disease (MRD) detection. Numerous clinical trials are currently evaluating treatment strategies using ctDNA testing. In particular, the implementation of adjuvant treatment escalation or de-escalation based on MRD detection could dramatically transform future approaches to solid tumor treatment. Various ctDNA assays have been developed, and it is important to understand their strengths and weaknesses for effective clinical applications. Furthermore, ctDNA testing faces several technical challenges, including low sensitivity in detecting copy number alterations and fusions, as well as the possibility of detecting mutations associated with clonal hematopoiesis of indeterminate potential. In this review, we comprehensively discuss the methodologies and recent advancements in cfDNA-based liquid biopsies for cancer patients, covering diagnosis, genomic profiling, and treatment monitoring. Furthermore, we explore clinical trial designs employing ctDNA testing and anticipate forthcoming changes in patient care.

PMID:40915174 | PMC:PMC12450568 | DOI:10.1016/j.tranon.2025.102519

  •  

Article: Virtual Panel: How Software Engineers and Team Leaders Can Excel with Artificial Intelligence

Artificial intelligence is impacting the individual work of software developers, how professionals work together in teams, and how software teams are being managed. In this panel, we'll discuss how artificial intelligence is reshaping software development, and what mindset and skills are required for software developers and engineering leaders to become adaptable and resilient in the age of AI.

By Ben Linders, Courtney Nash, Mandy Gu, Hien Luu
  •  

Scalable generation and functional classification of genetic variants in inborn errors of immunity to accelerate clinical diagnosis and treatment

In lieu of traditional genetic variant testing approaches, an approach using scalable variant classification in primary human T cells with a clinically relevant readout can inform rapid diagnosis and treatment of inborn errors of immunity.
  •  

STAMP: Single-cell transcriptomics analysis and multimodal profiling through imaging

Single-cell transcriptomics analysis and multimodal profiling (STAMP) by imaging enables single-cell analysis of cells in suspension without the need for sequencing. The markedly reduced costs and flexible experimental designs support the profiling of millions of cells or the large-scale multiplexing of conditions, perturbations, and sample types.
  •  

Meta revises AI chatbot policies amid child safety concerns

Meta is revising how its AI chatbots interact with users after a series of reports exposed troubling behaviour, including interactions with minors. The company told TechCrunch it is now training its bots not to engage with teenagers on topics like self-harm, suicide, or eating disorders, and to avoid romantic banter. These are temporary steps while it develops longer-term rules.

The changes follow a Reuters investigation that found Meta’s systems could generate sexualised content, including shirtless images of underage celebrities, and engage children in conversations that were romantic or suggestive. One case reported by the news agency described a man dying after rushing to an address provided by a chatbot in New York.

Meta spokesperson Stephanie Otway admitted the company had made mistakes. She said Meta is “training our AIs not to engage with teens on these topics, but to guide them to expert resources,” and confirmed that certain AI characters, like highly sexualised ones like “Russian Girl,” will be restricted.

Child safety advocates argue the company should have acted earlier. Andy Burrows of the Molly Rose Foundation called it “astounding” that bots were allowed to operate in ways that put young people at risk. He added: “While further safety measures are welcome, robust safety testing should take place before products are put on the market – not retrospectively when harm has taken place.”

Wider problems with AI misuse

The scrutiny of Meta’s AI chatbots comes amid broader worries about how AI chatbots may affect vulnerable users. A California couple recently filed a lawsuit against OpenAI, claiming ChatGPT encouraged their teenage son to take his own life. OpenAI has since said it is working on tools to promote healthier use of its technology, noting in a blog post that “AI can feel more responsive and personal than prior technologies, especially for vulnerable individuals experiencing mental or emotional distress.”

The incidents highlight a growing debate about whether AI firms are releasing products too quickly without proper safeguards. Lawmakers in several countries have already warned that chatbots, while useful, may amplify harmful content or give misleading advice to people who are not equipped to question it.

Meta’s AI Studio and chatbot impersonation issues

Meanwhile, Reuters reported that Meta’s AI Studio had been used to create flirtatious “parody” chatbots of celebrities like Taylor Swift and Scarlett Johansson. Testers found the bots often claimed to be the real people, engaged in sexual advances, and in some cases generated inappropriate images, including of minors. Although Meta removed several of the bots after being contacted by reporters, many were left active.

Some of the AI chatbots were created by outside users, but others came from inside Meta. One chatbot made by a product lead in its generative AI division impersonated Taylor Swift and invited a Reuters reporter to meet for a “romantic fling” on her tour bus. This was despite Meta’s policies explicitly banning sexually suggestive imagery and the direct impersonation of public figures.

The issue of AI chatbot impersonation is particularly sensitive. Celebrities face reputational risks when their likeness is misused, but experts point out that ordinary users can also be deceived. A chatbot pretending to be a friend, mentor, or romantic partner may encourage someone to share private information or even meet in unsafe situations.

Real-world risks

The problems are not confined to entertainment. AI chatbots posing as real people have offered fake addresses and invitations, raising questions about how Meta’s AI tools are being monitored. One example involved a 76-year-old man in New Jersey who died after falling while rushing to meet a chatbot that claimed to have feelings for him.

Cases like this illustrate why regulators are watching AI closely. The Senate and 44 state attorneys general have already begun probing Meta’s practices, adding political pressure to the company’s internal reforms. Their concern is not only about minors, but also about how AI could manipulate older or vulnerable users.

Meta says it is still working on improvements. Its platforms place users aged 13 to 18 into “teen accounts” with stricter content and privacy settings, but the company has not yet explained how it plans to address the full list of problems raised by Reuters. That includes bots offering false medical advice and generating racist content.

Ongoing pressure on Meta’s AI chatbot policies

For years, Meta has faced criticism over the safety of its social media platforms, particularly regarding children and teenagers. Now Meta’s AI chatbot experiments are drawing similar scrutiny. While the company is taking steps to restrict harmful chatbot behaviour, the gap between its stated policies and the way its tools have been used raises ongoing questions about whether it can enforce those rules.

Until stronger safeguards are in place, regulators, researchers, and parents will likely continue to press Meta on whether its AI is ready for public use.

(Photo by Maxim Tolchinskiy)

See also: Agentic AI: Promise, scepticism, and its meaning for Southeast Asia

Want to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is part of TechEx and co-located with other leading technology events. Click here for more information.

AI News is powered by TechForge Media. Explore other upcoming enterprise technology events and webinars here.

The post Meta revises AI chatbot policies amid child safety concerns appeared first on AI News.

  •  

Resident Preferences for Telemedicine Services in China in the Digital Health Era: Mixed Methods Study

Background: In the digital health era, telemedicine has become a key driver of health care reform and innovation globally. Understanding the factors influencing residents’ choices of telemedicine services is crucial for optimizing service design, enhancing user experience, and developing effective policy measures. Objective: This study aims to explore the key factors influencing Chinese residents’ choices of telemedicine services, including consultation fee, physician qualifications, appointment waiting time, scope of services, privacy protection, and service hours. The study also analyzes preference heterogeneity among residents with different demographic characteristics to provide scientific evidence for optimizing telemedicine services in the digital health era. Methods: This study used a mixed methods design combining qualitative interviews and a discrete choice experiment. Interviews identified key telemedicine attributes, informing the discrete choice experiment scenarios. Preferences and willingness to pay were analyzed using mixed logit and latent class models. Results: Residents’ preferences for telemedicine services were primarily shaped by the scope of services, appointment waiting time, and privacy protection, with substantial willingness to pay for more comprehensive, secure, and timely services. The optimal telemedicine services configuration—offering consultation plus prescription, high privacy, immediate access, 24-hour availability, and expert physicians—yielded a maximum willingness to pay of RMB 661.6 (a currency exchange rate of US $1=RMB 7.1803 is applicable). Latent class analysis revealed pronounced heterogeneity: while privacy and service scope remained universally prioritized, older, male, rural, and less-educated residents favored broader coverage, easier platforms, and lower costs; younger, female, and highly educated groups preferred faster, higher-quality, and more privacy-sensitive services. Conclusions: This study reveals key drivers and significant demographic heterogeneity in Chinese residents’ preferences for telemedicine services. Residents demonstrated a high willingness to pay for comprehensive services (eg, “consultation + prescription”), enhanced privacy protection, and shorter appointment waiting times. Additionally, the study innovatively identified 3 distinct resident profiles: “Diverse-Service-Oriented,” “Utility-Oriented,” and “Value-Oriented,” and proposed differentiated optimization strategies to effectively address diverse resident needs, thereby promoting equitable access and efficient adoption of telemedicine services.
  •  

Evolving Medical Students’ Digital Health Perceptions and Intentions: Insights From a Prepandemic and Postpandemic Survey Study

Background: The COVID-19 pandemic has underscored the importance of digital health (dHealth) technologies in medical practice. Despite this, medical curricula often provide limited exposure to these technologies. Objective: This study investigates the effects of the COVID-19 pandemic on medical students’ intentions to integrate dHealth technologies into their future practice. Methods: We employed a two-phase survey at the University of Montreal’s medical school to assess changes in perceptions before (N=184) and after (N=138) the pandemic. The survey used component-based structural equation modeling (SEM) and qualitative comparative analysis (QCA) to analyze our dataset. Results: Findings indicate limited exposure to dHealth technologies within the medical curriculum. However, there was a strong consensus on the necessity of formal dHealth training. A notable shift towards the acceptance of artificial intelligence (AI) and telehealth tools was observed, emphasizing the pandemic’s significant role in altering students' views on these technologies. Conclusions: The study advocates for the integration of formal dHealth training in medical curricula to better prepare future physicians for the demands of an increasingly digital healthcare landscape. The COVID-19 pandemic has significantly influenced medical students' perceptions, highlighting the urgent need to adapt medical education to include comprehensive dHealth training.
  •  

Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma

Nat Commun. 2025 Sep 1;16(1):8161. doi: 10.1038/s41467-025-63538-4.

ABSTRACT

Immune checkpoint blockade (ICB) has improved outcomes for patients with head and neck squamous cell carcinoma (HNSCC), but predictive biomarkers remain limited. Here, we use a time-resolved, multi-omic approach in a murine HNSCC model to characterize peripheral immune responses to ICB. Single-cell transcriptomics and T/B cell receptor analyses reveal early on-treatment expansion of effector memory T and B cell repertoires in responders, preceding tumor regression. These dynamic immune features inform a composite transcriptional signature that accurately predicts ICB response in independent human HNSCC cohorts. LiBIO outperforms existing biomarkers and generalizes to melanoma, non-small cell lung cancer, and breast cancer without retraining. These findings suggest that early treatment-induced changes in circulating immune repertoires reflect the host's capacity to mount an effective antitumor response. This work provides a framework for leveraging transient peripheral immune dynamics to develop non-invasive, high-fidelity biomarkers for response to immunotherapy across cancer types.

PMID:40890155 | PMC:PMC12402333 | DOI:10.1038/s41467-025-63538-4

  •  

Malaysia launches Ryt Bank, its first AI-powered bank

AI is steadily changing the way banks work. The technology can sift through massive amounts of data, calculate risks, and handle routine tasks at speeds people can’t match. Now, Malaysia has entered that space with the launch of Ryt Bank, billed as the first AI-powered bank created in the country.

The new venture, led by YTL Group in partnership with Sea Limited, arrives just ahead of Merdeka. “Ryt Bank demonstrates that groundbreaking innovation can be imagined, built, and led right here in Malaysia,” said Dato’ Seri Yeoh Seok Hong, Managing Director of YTL Power International. “By combining homegrown AI with the values and diversity of our people, we’ve created a bank that Malaysians can proudly call their own – one that speaks our languages, understands our culture, and sets a new standard for how banking should feel.”

Banking for Malaysians

Ryt Bank has been designed to work in the languages most Malaysians use every day. Its app is already available in Bahasa Malaysia and English, with Mandarin support scheduled to arrive by next month (September 2025). By offering multilingual access, the bank aims to make financial services more inclusive and easy to use for people in many different communities.

The centrepiece of the AI-powered bank is Ryt AI, a digital assistant powered by ILMU, Malaysia’s first locally-developed large language model. Ryt AI can understand natural conversation – in Bahasa Malaysia, English, or a mixture of both – and act on requests instantly.

The AI assistant can read and pay bills, track spending, and explain financial basics in plain terms. The idea is to blend convenience with cultural familiarity, while maintaining enterprise-grade security.

Everyday AI banking in one app

Ryt Bank is designed to pull together multiple financial needs into one platform. Customers can use the AI bank app to save, spend, borrow, and pay bills, with Ryt AI making the process more conversational and personal.

Personal banking with Ryt AI

  • Send money or pay bills through text chat, with support for DuitNow and JomPAY.
  • Snap and upload bills or receipts for instant payment.
  • Access guides and simple financial explanations as you bank.
  • All actions are encrypted and verified for security.
  • New users can claim a small launch reward of up to RM5 when they try Ryt AI.

Growing money

  • Customers earn up to 4% interest per year, credited daily.
  • Withdraw funds anytime, with no lock-in requirements.

Ryt PayLater

  • Access instant credit of up to RM1,499.
  • 0% interest if paid back in a month.
  • No late fees and no paperwork.
  • Earn cashback on DuitNow QR payments and extra rewards with select partners.

Ryt Card

  • Switch between debit and credit card models in the app.
  • Accepted worldwide through Visa.
  • No foreign transaction or ATM fees in Malaysia.
  • Cashback on spending, plus partner offers like Shopee vouchers and dining discounts at YTL Hotels.

[See also: Can Malaysia become Southeast Asia’s AI and cloud hub?]

Banking under Bank Negara rules

The AI bank is licensed by Bank Negara Malaysia and covered by PIDM, which protects deposits up to RM250,000 per customer. Security features include biometric login, layered encryption, and real-time fraud alerts.

A step forward for Malaysia’s banking sector

Ryt Bank’s launch shows how AI is being used to rethink traditional banking. It aims to make financial services more accessible and satisfy regulatory and security standards by supporting local languages and developing its own AI assistant.

See also: Huawei commits to training 30,000 Malaysian AI professionals as local tech ecosystem expands

Want to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is co-located with other leading events including Intelligent Automation Conference, BlockX, Digital Transformation Week, and Cyber Security & Cloud Expo.

Explore other upcoming enterprise technology events and webinars powered by TechForge here.

The post Malaysia launches Ryt Bank, its first AI-powered bank appeared first on AI News.

  •  

An eyecare foundation model for clinical assistance: a randomized controlled trial

Nature Medicine, Published online: 28 August 2025; doi:10.1038/s41591-025-03900-7

Trained and validated on multimodal data from 14.5 million images from multicountry datasets, a foundation model is shown to increase diagnostic and referral accuracy of clinicians when used as an assistant in a trial involving 16 ophthalmologists and 668 patients.
  •  

Stereo-seq V2: Spatial mapping of total RNA on FFPE sections with high resolution

Cell. 2025 Aug 22:S0092-8674(25)00922-5. doi: 10.1016/j.cell.2025.08.008. Online ahead of print.

ABSTRACT

Performing total RNA profiling on formalin-fixed, paraffin-embedded (FFPE) samples, the predominant sample conservation method in clinical practice, remains challenging for current spatial transcriptomics techniques. Here, we introduce Stereo-seq V2, which employs random primers to capture and sequence RNAs in situ on FFPE sections and provides single-cell resolution. The random-priming-based strategy offers unbiased transcript capturing and uniform gene body coverage, which increase the sensitivity to marker genes, the efficiency of non-polyadenylation (poly(A)) RNA profiling, and immune repertoire coverage. We demonstrated the robust performance of Stereo-seq V2 on clinical FFPE samples using triple-negative breast cancer (TNBC) sections and identified tumor-specific alternative splicing events. In a Mycobacterium tuberculosis (Mtb)-infected mouse model, we monitored gene expression dynamics of host and pathogen transcriptomes simultaneously by utilizing Stereo-seq V2. We also assembled immune repertoires and identified Mtb-specific BCR clones, which could also be observed in human tuberculous lung samples. These results highlight Stereo-seq V2's potential in biomedical research and personalized medicine.

PMID:40882628 | DOI:10.1016/j.cell.2025.08.008

  •  

Global Hypomethylation as Minimal Residual Disease (MRD) Biomarker in Esophageal and Esophagogastric Junction Adenocarcinoma

Cancers (Basel). 2025 Aug 15;17(16):2668. doi: 10.3390/cancers17162668.

ABSTRACT

Background/Objectives: Esophageal and esophagogastric junction adenocarcinoma (EADC-EGJA), which mainly develops from Barrett's esophagus (BE), low-grade dysplasia (LGD), and high-grade dysplasia (HGD), has a poor prognosis and several unmet clinical needs, among which is the detection of minimal residual disease (MRD) after endoscopic/surgical resection. Long interspersed nuclear element-1 (LINE-1), a surrogate marker of global methylation, is considered an emerging biomarker for MRD monitoring. The aim of this study was to determine, by LINE-1 methylation analysis, at which carcinogenesis step global methylation is affected and whether this biomarker could be followed in longitudinal to monitor the disease behavior post-surgery. Methods: Cell-free DNA of 90 patients with non-dysplastic Barrett's esophagus (NDBE), HGD/early EADC-EGJA, or locally advanced/advanced EADC-EGJA were analyzed for LINE-1 methylation, by Methylation-Sensitive Restriction Enzyme droplet digital PCR (MSRE-ddPCR). Twenty-six patients were longitudinally studied by repetitive blood sampling. Results: Global hypomethylation increased during carcinogenesis, with significant difference between locally advanced/advanced EADC-EGJA and NDBE patients (p = 0.028). Longitudinal cases confirmed the rareness of hypomethylation in NDBE cases. The majority of HGD/early EADC-EGJA and locally advanced/advanced EADC-EGJA patients showed methylation changes after resection according to clinical status. Conclusions: This study suggests that global hypomethylation occurs just prior to cancer invasiveness and that it is a promising biomarker to monitor MRD.

PMID:40867295 | PMC:PMC12384112 | DOI:10.3390/cancers17162668

  •  
❌